#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Altered	_
1-2	8-18	functional	_
1-3	19-31	connectivity	_
1-4	32-39	between	_
1-5	40-51	sub-regions	_
1-6	52-54	in	_
1-7	55-58	the	_
1-8	59-67	thalamus	_
1-9	68-71	and	_
1-10	72-78	cortex	_
1-11	79-81	in	_
1-12	82-95	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	96-104	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	105-113	measured	_
1-15	114-116	by	_
1-16	117-124	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-17	125-130	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-18	131-135	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-19	136-140	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-20	141-143	at	_
1-21	144-146	7T	_
1-22	147-150	The	_
1-23	151-159	thalamus	_
1-24	160-162	is	_
1-25	163-164	a	_
1-26	165-170	small	_
1-27	171-176	brain	_
1-28	177-186	structure	_
1-29	187-191	that	_
1-30	192-198	relays	_
1-31	199-207	neuronal	_
1-32	208-215	signals	_
1-33	216-223	between	_
1-34	224-235	subcortical	_
1-35	236-239	and	_
1-36	240-248	cortical	_
1-37	249-256	regions	_
1-38	257-258	.	_

2-1	259-267	Abnormal	_
2-2	268-283	thalamocortical	_
2-3	284-296	connectivity	_
2-4	297-299	in	_
2-5	300-313	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-6	314-317	has	_
2-7	318-322	been	_
2-8	323-331	reported	_
2-9	332-334	in	_
2-10	335-343	previous	_
2-11	344-351	studies	_
2-12	352-357	using	_
2-13	358-391	blood-oxygenation-level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-14	392-393	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-15	394-398	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-16	399-400	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-17	401-411	functional	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-18	412-415	MRI	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-19	416-417	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-20	418-422	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-21	423-424	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
2-22	425-434	performed	_
2-23	435-437	at	_
2-24	438-440	3T	http://maven.renci.org/NeuroBridge/neurobridge#Thing
2-25	441-442	.	_

3-1	443-450	However	_
3-2	451-452	,	_
3-3	453-465	anatomically	_
3-4	466-469	the	_
3-5	470-478	thalamus	_
3-6	479-481	is	_
3-7	482-485	not	_
3-8	486-487	a	_
3-9	488-494	single	_
3-10	495-501	entity	_
3-11	502-503	,	_
3-12	504-507	but	_
3-13	508-510	is	_
3-14	511-521	subdivided	_
3-15	522-526	into	_
3-16	527-535	multiple	_
3-17	536-544	distinct	_
3-18	545-551	nuclei	_
3-19	552-556	with	_
3-20	557-566	different	_
3-21	567-578	connections	_
3-22	579-581	to	_
3-23	582-589	various	_
3-24	590-598	cortical	_
3-25	599-606	regions	_
3-26	607-608	.	_

4-1	609-611	We	_
4-2	612-618	sought	_
4-3	619-621	to	_
4-4	622-631	determine	_
4-5	632-635	the	_
4-6	636-645	potential	_
4-7	646-653	benefit	_
4-8	654-656	of	_
4-9	657-662	using	_
4-10	663-666	the	_
4-11	667-675	enhanced	_
4-12	676-687	sensitivity	_
4-13	688-690	of	_
4-14	691-695	BOLD	_
4-15	696-700	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-16	701-703	at	_
4-17	704-714	ultra-high	_
4-18	715-723	magnetic	_
4-19	724-729	field	_
4-20	730-731	(	_
4-21	732-734	7T	_
4-22	735-736	)	_
4-23	737-739	in	_
4-24	740-749	exploring	_
4-25	750-766	thalamo-cortical	_
4-26	767-779	connectivity	_
4-27	780-782	in	_
4-28	783-796	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-29	797-802	based	_
4-30	803-805	on	_
4-31	806-816	subregions	_
4-32	817-819	in	_
4-33	820-823	the	_
4-34	824-832	thalamus	_
4-35	833-834	.	_

5-1	835-840	Seeds	_
5-2	841-847	placed	_
5-3	848-850	in	_
5-4	851-859	thalamic	_
5-5	860-870	subregions	_
5-6	871-873	of	_
5-7	874-876	14	_
5-8	877-885	patients	_
5-9	886-889	and	_
5-10	890-892	14	_
5-11	893-900	matched	_
5-12	901-909	controls	_
5-13	910-914	were	_
5-14	915-919	used	_
5-15	920-922	to	_
5-16	923-932	calculate	_
5-17	933-944	whole-brain	_
5-18	945-955	functional	_
5-19	956-968	connectivity	_
5-20	969-970	.	_

6-1	971-974	Our	_
6-2	975-982	results	_
6-3	983-994	demonstrate	_
6-4	995-1003	impaired	_
6-5	1004-1012	thalamic	_
6-6	1013-1025	connectivity	_
6-7	1026-1028	to	_
6-8	1029-1032	the	_
6-9	1033-1043	prefrontal	_
6-10	1044-1050	cortex	_
6-11	1051-1054	and	_
6-12	1055-1058	the	_
6-13	1059-1069	cerebellum	_
6-14	1070-1071	,	_
6-15	1072-1075	but	_
6-16	1076-1084	enhanced	_
6-17	1085-1093	thalamic	_
6-18	1094-1106	connectivity	_
6-19	1107-1109	to	_
6-20	1110-1113	the	_
6-21	1114-1127	motor/sensory	_
6-22	1128-1134	cortex	_
6-23	1135-1137	in	_
6-24	1138-1151	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-25	1152-1153	.	_

7-1	1154-1158	This	_
7-2	1159-1166	altered	_
7-3	1167-1177	functional	_
7-4	1178-1190	connectivity	_
7-5	1191-1204	significantly	_
7-6	1205-1215	correlated	_
7-7	1216-1220	with	_
7-8	1221-1228	disease	_
7-9	1229-1237	duration	_
7-10	1238-1240	in	_
7-11	1241-1244	the	_
7-12	1245-1253	patients	_
7-13	1254-1255	.	_

8-1	1256-1266	Remarkably	_
8-2	1267-1268	,	_
8-3	1269-1279	comparable	_
8-4	1280-1286	effect	_
8-5	1287-1292	sizes	_
8-6	1293-1301	observed	_
8-7	1302-1304	in	_
8-8	1305-1313	previous	_
8-9	1314-1316	3T	_
8-10	1317-1324	studies	_
8-11	1325-1329	were	_
8-12	1330-1338	detected	_
8-13	1339-1341	in	_
8-14	1342-1345	the	_
8-15	1346-1353	current	_
8-16	1354-1356	7T	_
8-17	1357-1362	study	_
8-18	1363-1367	with	_
8-19	1368-1369	a	_
8-20	1370-1383	heterogeneous	_
8-21	1384-1387	and	_
8-22	1388-1392	much	_
8-23	1393-1400	smaller	_
8-24	1401-1407	cohort	_
8-25	1408-1409	,	_
8-26	1410-1419	providing	_
8-27	1420-1428	evidence	_
8-28	1429-1433	that	_
8-29	1434-1444	ultra-high	_
8-30	1445-1450	field	_
8-31	1451-1455	fMRI	_
8-32	1456-1459	may	_
8-33	1460-1462	be	_
8-34	1463-1464	a	_
8-35	1465-1473	powerful	_
8-36	1474-1478	tool	_
8-37	1479-1482	for	_
8-38	1483-1492	measuring	_
8-39	1493-1503	functional	_
8-40	1504-1516	connectivity	_
8-41	1517-1530	abnormalities	_
8-42	1531-1533	in	_
8-43	1534-1547	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-44	1548-1549	.	_

9-1	1550-1557	Further	_
9-2	1558-1571	investigation	_
9-3	1572-1576	with	_
9-4	1577-1578	a	_
9-5	1579-1585	larger	_
9-6	1586-1592	cohort	_
9-7	1593-1595	is	_
9-8	1596-1603	merited	_
9-9	1604-1606	to	_
9-10	1607-1615	validate	_
9-11	1616-1619	the	_
9-12	1620-1627	current	_
9-13	1628-1636	findings	_
9-14	1637-1638	.	_

10-1	1639-1646	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	1647-1659	Participants	_
10-3	1660-1668	Fourteen	_
10-4	1669-1677	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-5	1678-1682	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-6	1683-1684	a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-7	1685-1694	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-8	1695-1697	of	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-9	1698-1711	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-10	1712-1713	(	_
10-11	1714-1715	n	_
10-12	1716-1717	=	_
10-13	1718-1720	12	_
10-14	1721-1722	)	_
10-15	1723-1725	or	_
10-16	1726-1741	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
10-17	1742-1743	(	_
10-18	1744-1745	n	_
10-19	1746-1747	=	_
10-20	1748-1749	2	_
10-21	1750-1751	)	_
10-22	1752-1760	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
10-23	1761-1764	and	_
10-24	1765-1773	fourteen	_
10-25	1774-1777	age	_
10-26	1778-1781	and	_
10-27	1782-1785	sex	_
10-28	1786-1793	matched	_
10-29	1794-1800	normal	_
10-30	1801-1809	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-31	1810-1814	were	_
10-32	1815-1824	recruited	_
10-33	1825-1828	and	_
10-34	1829-1836	scanned	_
10-35	1837-1846	following	_
10-36	1847-1848	a	_
10-37	1849-1854	Johns	_
10-38	1855-1862	Hopkins	_
10-39	1863-1871	Medicine	_
10-40	1872-1885	Institutional	_
10-41	1886-1892	Review	_
10-42	1893-1898	Board	_
10-43	1899-1907	approved	_
10-44	1908-1916	protocol	_
10-45	1917-1918	.	_

11-1	1919-1922	All	_
11-2	1923-1935	participants	_
11-3	1936-1940	gave	_
11-4	1941-1948	written	_
11-5	1949-1957	informed	_
11-6	1958-1965	consent	_
11-7	1966-1972	before	_
11-8	1973-1981	scanning	_
11-9	1982-1983	.	_

12-1	1984-1988	None	_
12-2	1989-1991	of	_
12-3	1992-1995	the	_
12-4	1996-2004	subjects	_
12-5	2005-2008	had	_
12-6	2009-2014	other	_
12-7	2015-2025	neurologic	_
12-8	2026-2033	history	_
12-9	2034-2036	or	_
12-10	2037-2049	neurological	_
12-11	2050-2055	signs	_
12-12	2056-2058	on	_
12-13	2059-2063	exam	_
12-14	2064-2065	,	_
12-15	2066-2068	or	_
12-16	2069-2070	a	_
12-17	2071-2078	history	_
12-18	2079-2081	of	_
12-19	2082-2090	vascular	_
12-20	2091-2099	diseases	_
12-21	2100-2101	.	_

13-1	2102-2104	As	_
13-2	2105-2112	tobacco	_
13-3	2113-2120	smoking	_
13-4	2121-2126	could	_
13-5	2127-2138	potentially	_
13-6	2139-2145	affect	_
13-7	2146-2154	baseline	_
13-8	2155-2160	brain	_
13-9	2161-2170	perfusion	_
13-10	2171-2174	and	_
13-11	2175-2179	thus	_
13-12	2180-2183	the	_
13-13	2184-2188	BOLD	_
13-14	2189-2195	effect	_
13-15	2196-2197	,	_
13-16	2198-2205	current	_
13-17	2206-2213	smoking	_
13-18	2214-2220	status	_
13-19	2221-2222	(	_
13-20	2223-2233	cigarettes	_
13-21	2234-2240	smoked	_
13-22	2241-2244	per	_
13-23	2245-2248	day	_
13-24	2249-2250	)	_
13-25	2251-2254	was	_
13-26	2255-2265	determined	_
13-27	2266-2269	for	_
13-28	2270-2278	patients	_
13-29	2279-2282	and	_
13-30	2283-2291	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-31	2292-2293	.	_

14-1	2294-2301	Current	_
14-2	2302-2315	schizophrenia	_
14-3	2316-2323	symptom	_
14-4	2324-2332	severity	_
14-5	2333-2336	was	_
14-6	2337-2345	assessed	_
14-7	2346-2350	with	_
14-8	2351-2354	the	_
14-9	2355-2360	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-10	2361-2372	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-11	2373-2379	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-12	2380-2385	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-13	2386-2387	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-14	2388-2392	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-15	2393-2394	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
14-16	2395-2396	.	_

15-1	2397-2406	Diagnosis	_
15-2	2407-2410	was	_
15-3	2411-2416	based	_
15-4	2417-2419	on	_
15-5	2420-2428	clinical	_
15-6	2429-2436	records	_
15-7	2437-2440	and	_
15-8	2441-2449	clinical	_
15-9	2450-2459	referrals	_
15-10	2460-2462	at	_
15-11	2463-2466	the	_
15-12	2467-2472	point	_
15-13	2473-2475	of	_
15-14	2476-2489	ascertainment	_
15-15	2490-2491	,	_
15-16	2492-2495	and	_
15-17	2496-2499	was	_
15-18	2500-2509	confirmed	_
15-19	2510-2512	by	_
15-20	2513-2520	symptom	_
15-21	2521-2531	evaluation	_
15-22	2532-2534	on	_
15-23	2535-2540	entry	_
15-24	2541-2545	into	_
15-25	2546-2549	the	_
15-26	2550-2555	study	_
15-27	2556-2557	.	_

16-1	2558-2561	All	_
16-2	2562-2570	patients	_
16-3	2571-2572	,	_
16-4	2573-2576	but	_
16-5	2577-2581	none	_
16-6	2582-2584	of	_
16-7	2585-2588	the	_
16-8	2589-2597	controls	_
16-9	2598-2599	,	_
16-10	2600-2604	were	_
16-11	2605-2614	receiving	_
16-12	2615-2628	antipsychotic	_
16-13	2629-2638	medicines	_
16-14	2639-2640	.	_

17-1	2641-2648	Current	_
17-2	2649-2663	chlorpromazine	_
17-3	2664-2665	(	_
17-4	2666-2669	CPZ	_
17-5	2670-2671	)	_
17-6	2672-2683	equivalents	_
17-7	2684-2688	were	_
17-8	2689-2693	used	_
17-9	2694-2696	as	_
17-10	2697-2698	a	_
17-11	2699-2704	proxy	_
17-12	2705-2708	for	_
17-13	2709-2717	lifetime	_
17-14	2718-2731	antipsychotic	_
17-15	2732-2740	exposure	_
17-16	2741-2742	.	_

18-1	2743-2746	The	_
18-2	2747-2755	Montreal	_
18-3	2756-2765	Cognitive	_
18-4	2766-2776	Assessment	_
18-5	2777-2778	(	_
18-6	2779-2783	MoCA	_
18-7	2784-2785	)	_
18-8	2786-2789	was	_
18-9	2790-2799	performed	_
18-10	2800-2802	on	_
18-11	2803-2807	each	_
18-12	2808-2819	participant	_
18-13	2820-2822	on	_
18-14	2823-2826	the	_
18-15	2827-2830	day	_
18-16	2831-2833	of	_
18-17	2834-2842	scanning	_
18-18	2843-2844	.	_

19-1	2845-2848	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-2	2849-2852	All	_
19-3	2853-2858	scans	_
19-4	2859-2863	were	_
19-5	2864-2873	performed	_
19-6	2874-2876	on	_
19-7	2877-2878	a	_
19-8	2879-2881	7T	_
19-9	2882-2889	Philips	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-10	2890-2893	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-11	2894-2901	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-12	2902-2903	(	_
19-13	2904-2911	Philips	_
19-14	2912-2922	Healthcare	_
19-15	2923-2924	,	_
19-16	2925-2929	Best	_
19-17	2930-2931	,	_
19-18	2932-2935	The	_
19-19	2936-2947	Netherlands	_
19-20	2948-2949	)	_
19-21	2950-2951	.	_

20-1	2952-2953	A	_
20-2	2954-2964	32-channel	_
20-3	2965-2977	phased-array	_
20-4	2978-2982	head	_
20-5	2983-2987	coil	_
20-6	2988-2989	(	_
20-7	2990-2994	Nova	_
20-8	2995-3002	Medical	_
20-9	3003-3004	,	_
20-10	3005-3015	Wilmington	_
20-11	3016-3017	,	_
20-12	3018-3020	MA	_
20-13	3021-3022	)	_
20-14	3023-3026	was	_
20-15	3027-3031	used	_
20-16	3032-3035	for	_
20-17	3036-3038	RF	_
20-18	3039-3048	reception	_
20-19	3049-3052	and	_
20-20	3053-3054	a	_
20-21	3055-3064	head-only	_
20-22	3065-3075	quadrature	_
20-23	3076-3080	coil	_
20-24	3081-3084	for	_
20-25	3085-3093	transmit	_
20-26	3094-3095	.	_

21-1	3096-3111	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-2	3112-3122	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-3	3123-3129	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-4	3130-3134	were	_
21-5	3135-3143	acquired	_
21-6	3144-3148	with	_
21-7	3149-3150	a	_
21-8	3151-3153	3D	_
21-9	3154-3167	magnetization	_
21-10	3168-3176	prepared	_
21-11	3177-3178	2	_
21-12	3179-3184	rapid	_
21-13	3185-3196	acquisition	_
21-14	3197-3205	gradient	_
21-15	3206-3212	echoes	_
21-16	3213-3214	(	_
21-17	3215-3222	MP2RAGE	_
21-18	3223-3224	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-19	3225-3233	sequence	_
21-20	3234-3235	(	_
21-21	3236-3241	voxel	_
21-22	3242-3243	=	_
21-23	3244-3248	0.65	_
21-24	3249-3251	mm	_
21-25	3252-3261	isotropic	_
21-26	3262-3263	)	_
21-27	3264-3266	to	_
21-28	3267-3275	minimize	_
21-29	3276-3278	B1	_
21-30	3279-3284	field	_
21-31	3285-3298	inhomogeneity	_
21-32	3299-3306	induced	_
21-33	3307-3316	artifacts	_
21-34	3317-3319	at	_
21-35	3320-3322	7T	_
21-36	3323-3324	.	_

22-1	3325-3326	A	_
22-2	3327-3334	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-3	3335-3340	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-4	3341-3345	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-5	3346-3350	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-6	3351-3354	was	_
22-7	3355-3364	performed	_
22-8	3365-3369	with	_
22-9	3370-3378	gradient	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-10	3379-3383	echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-11	3384-3385	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-12	3386-3389	GRE	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-13	3390-3391	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-14	3392-3403	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-15	3404-3411	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-16	3412-3413	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-17	3414-3417	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-18	3418-3419	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
22-19	3420-3421	(	_
22-20	3422-3444	TR/TE/FA=2000/22ms/60°	_
22-21	3445-3446	,	_
22-22	3447-3458	voxel=2.5mm	_
22-23	3459-3468	isotropic	_
22-24	3469-3470	,	_
22-25	3471-3473	54	_
22-26	3474-3480	slices	_
22-27	3481-3482	,	_
22-28	3483-3484	7	_
22-29	3485-3492	minutes	_
22-30	3493-3494	)	_
22-31	3495-3498	for	_
22-32	3499-3503	each	_
22-33	3504-3515	participant	_
22-34	3516-3517	.	_

23-1	3518-3522	Data	_
23-2	3523-3531	analysis	_
23-3	3532-3535	The	_
23-4	3536-3547	statistical	_
23-5	3548-3558	parametric	_
23-6	3559-3566	mapping	_
23-7	3567-3568	(	_
23-8	3569-3572	SPM	_
23-9	3573-3574	)	_
23-10	3575-3583	software	_
23-11	3584-3591	package	_
23-12	3592-3593	(	_
23-13	3594-3601	Version	_
23-14	3602-3603	8	_
23-15	3604-3605	,	_
23-16	3606-3614	Wellcome	_
23-17	3615-3620	Trust	_
23-18	3621-3627	Centre	_
23-19	3628-3631	for	_
23-20	3632-3644	Neuroimaging	_
23-21	3645-3646	,	_
23-22	3647-3653	London	_
23-23	3654-3655	,	_
23-24	3656-3662	United	_
23-25	3663-3670	Kingdom	_
23-26	3671-3672	;	_
23-27	3673-3677	http	_
23-28	3678-3679	:	_
23-29	3680-3708	//www.fil.ion.ucl.ac.uk/spm/	_
23-30	3709-3710	)	_
23-31	3711-3714	and	_
23-32	3715-3723	in-house	_
23-33	3724-3728	code	_
23-34	3729-3739	programmed	_
23-35	3740-3742	in	_
23-36	3743-3749	Matlab	_
23-37	3750-3751	(	_
23-38	3752-3761	MathWorks	_
23-39	3762-3763	,	_
23-40	3764-3770	Natick	_
23-41	3771-3772	,	_
23-42	3773-3775	MA	_
23-43	3776-3777	,	_
23-44	3778-3781	USA	_
23-45	3782-3783	)	_
23-46	3784-3788	were	_
23-47	3789-3793	used	_
23-48	3794-3797	for	_
23-49	3798-3803	image	_
23-50	3804-3812	analysis	_
23-51	3813-3814	.	_

24-1	3815-3828	Preprocessing	_
24-2	3829-3837	included	_
24-3	3838-3849	realignment	_
24-4	3850-3851	,	_
24-5	3852-3857	slice	_
24-6	3858-3862	time	_
24-7	3863-3873	correction	_
24-8	3874-3875	,	_
24-9	3876-3891	co-registration	_
24-10	3892-3893	,	_
24-11	3894-3906	segmentation	_
24-12	3907-3908	,	_
24-13	3909-3922	normalization	_
24-14	3923-3924	;	_
24-15	3925-3933	nuisance	_
24-16	3934-3941	removal	_
24-17	3942-3943	(	_
24-18	3944-3951	CompCor	_
24-19	3952-3953	)	_
24-20	3954-3955	,	_
24-21	3956-3966	regression	_
24-22	3967-3969	of	_
24-23	3970-3976	global	_
24-24	3977-3981	mean	_
24-25	3982-3985	and	_
24-26	3986-3992	motion	_
24-27	3993-4003	parameters	_
24-28	4004-4005	(	_
24-29	4006-4007	6	_
24-30	4008-4013	rigid	_
24-31	4014-4018	body	_
24-32	4019-4025	motion	_
24-33	4026-4036	correction	_
24-34	4037-4047	parameters	_
24-35	4048-4056	computed	_
24-36	4057-4061	from	_
24-37	4062-4065	the	_
24-38	4066-4069	SPM	_
24-39	4070-4081	realignment	_
24-40	4082-4089	routine	_
24-41	4090-4091	,	_
24-42	4092-4095	and	_
24-43	4096-4099	the	_
24-44	4100-4105	first	_
24-45	4106-4116	derivative	_
24-46	4117-4119	of	_
24-47	4120-4124	each	_
24-48	4125-4134	parameter	_
24-49	4135-4136	)	_
24-50	4137-4138	;	_
24-51	4139-4142	and	_
24-52	4143-4151	temporal	_
24-53	4152-4161	filtering	_
24-54	4162-4163	(	_
24-55	4164-4174	0.01–0.1Hz	_
24-56	4175-4176	)	_
24-57	4177-4178	.	_

25-1	4179-4184	Given	_
25-2	4185-4188	the	_
25-3	4189-4197	emerging	_
25-4	4198-4206	concerns	_
25-5	4207-4211	that	_
25-6	4212-4217	micro	_
25-7	4218-4227	movements	_
25-8	4228-4231	can	_
25-9	4232-4238	affect	_
25-10	4239-4246	between	_
25-11	4247-4252	group	_
25-12	4253-4264	differences	_
25-13	4265-4267	in	_
25-14	4268-4278	functional	_
25-15	4279-4291	connectivity	_
25-16	4292-4296	data	_
25-17	4297-4301	even	_
25-18	4302-4307	after	_
25-19	4308-4316	standard	_
25-20	4317-4323	motion	_
25-21	4324-4334	correction	_
25-22	4335-4345	procedures	_
25-23	4346-4347	,	_
25-24	4348-4350	we	_
25-25	4351-4358	applied	_
25-26	4359-4361	an	_
25-27	4362-4372	additional	_
25-28	4373-4374	“	_
25-29	4375-4384	scrubbing	_
25-30	4385-4386	”	_
25-31	4387-4396	procedure	_
25-32	4397-4406	described	_
25-33	4407-4409	in	_
25-34	4410-4418	previous	_
25-35	4419-4424	works	_
25-36	4425-4426	.	_

26-1	4427-4434	Briefly	_
26-2	4435-4436	,	_
26-3	4437-4440	the	_
26-4	4441-4442	6	_
26-5	4443-4448	rigid	_
26-6	4449-4453	body	_
26-7	4454-4460	motion	_
26-8	4461-4471	correction	_
26-9	4472-4482	parameters	_
26-10	4483-4487	were	_
26-11	4488-4497	converted	_
26-12	4498-4502	into	_
26-13	4503-4506	the	_
26-14	4507-4516	Framewise	_
26-15	4517-4529	Displacement	_
26-16	4530-4531	(	_
26-17	4532-4534	FD	_
26-18	4535-4536	)	_
26-19	4537-4539	by	_
26-20	4540-4547	summing	_
26-21	4548-4551	the	_
26-22	4552-4560	absolute	_
26-23	4561-4566	value	_
26-24	4567-4569	of	_
26-25	4570-4573	the	_
26-26	4574-4575	3	_
26-27	4576-4587	differenced	_
26-28	4588-4601	translational	_
26-29	4602-4612	parameters	_
26-30	4613-4616	and	_
26-31	4617-4620	the	_
26-32	4621-4622	3	_
26-33	4623-4634	differenced	_
26-34	4635-4645	rotational	_
26-35	4646-4656	parameters	_
26-36	4657-4658	.	_

27-1	4659-4661	An	_
27-2	4662-4664	FD	_
27-3	4665-4674	threshold	_
27-4	4675-4677	of	_
27-5	4678-4680	.5	_
27-6	4681-4683	mm	_
27-7	4684-4687	was	_
27-8	4688-4692	used	_
27-9	4693-4695	to	_
27-10	4696-4704	identify	_
27-11	4705-4716	potentially	_
27-12	4717-4736	motion-contaminated	_
27-13	4737-4742	scans	_
27-14	4743-4744	,	_
27-15	4745-4748	and	_
27-16	4749-4752	one	_
27-17	4753-4757	scan	_
27-18	4758-4764	before	_
27-19	4765-4768	and	_
27-20	4769-4770	2	_
27-21	4771-4776	scans	_
27-22	4777-4782	after	_
27-23	4783-4787	each	_
27-24	4788-4790	of	_
27-25	4791-4796	these	_
27-26	4797-4802	scans	_
27-27	4803-4808	above	_
27-28	4809-4812	the	_
27-29	4813-4815	FD	_
27-30	4816-4825	threshold	_
27-31	4826-4830	were	_
27-32	4831-4839	excluded	_
27-33	4840-4844	from	_
27-34	4845-4852	further	_
27-35	4853-4861	analysis	_
27-36	4862-4863	.	_

28-1	4864-4867	All	_
28-2	4868-4876	analysis	_
28-3	4877-4880	was	_
28-4	4881-4885	also	_
28-5	4886-4894	repeated	_
28-6	4895-4902	without	_
28-7	4903-4906	the	_
28-8	4907-4913	global	_
28-9	4914-4920	signal	_
28-10	4921-4931	regression	_
28-11	4932-4933	(	_
28-12	4934-4937	GSR	_
28-13	4938-4939	)	_
28-14	4940-4944	step	_
28-15	4945-4946	.	_

29-1	4947-4949	To	_
29-2	4950-4957	perform	_
29-3	4958-4968	seed-based	_
29-4	4969-4979	functional	_
29-5	4980-4992	connectivity	_
29-6	4993-5001	analysis	_
29-7	5002-5009	between	_
29-8	5010-5022	sub-thalamic	_
29-9	5023-5030	regions	_
29-10	5031-5034	and	_
29-11	5035-5038	the	_
29-12	5039-5044	brain	_
29-13	5045-5046	,	_
29-14	5047-5050	the	_
29-15	5051-5057	Oxford	_
29-16	5058-5066	thalamic	_
29-17	5067-5079	connectivity	_
29-18	5080-5085	atlas	_
29-19	5086-5089	was	_
29-20	5090-5098	employed	_
29-21	5099-5100	.	_

30-1	5101-5105	This	_
30-2	5106-5111	atlas	_
30-3	5112-5115	was	_
30-4	5116-5125	generated	_
30-5	5126-5131	using	_
30-6	5132-5141	diffusion	_
30-7	5142-5147	based	_
30-8	5148-5158	structural	_
30-9	5159-5171	connectivity	_
30-10	5172-5174	in	_
30-11	5175-5180	white	_
30-12	5181-5187	matter	_
30-13	5188-5195	between	_
30-14	5196-5199	the	_
30-15	5200-5208	thalamus	_
30-16	5209-5212	and	_
30-17	5213-5219	cortex	_
30-18	5220-5221	,	_
30-19	5222-5227	which	_
30-20	5228-5236	segments	_
30-21	5237-5240	the	_
30-22	5241-5249	thalamus	_
30-23	5250-5254	into	_
30-24	5255-5260	seven	_
30-25	5261-5272	sub-regions	_
30-26	5273-5274	,	_
30-27	5275-5279	with	_
30-28	5280-5281	>	_
30-29	5282-5284	25	_
30-30	5285-5286	%	_
30-31	5287-5298	probability	_
30-32	5299-5301	of	_
30-33	5302-5312	connection	_
30-34	5313-5315	to	_
30-35	5316-5321	seven	_
30-36	5322-5331	exclusive	_
30-37	5332-5340	cortical	_
30-38	5341-5346	areas	_
30-39	5347-5348	,	_
30-40	5349-5361	respectively	_
30-41	5362-5363	(	_
30-42	5364-5370	Figure	_
30-43	5371-5372	1	_
30-44	5373-5374	)	_
30-45	5375-5376	.	_

31-1	5377-5387	Seed-based	_
31-2	5388-5396	analysis	_
31-3	5397-5400	was	_
31-4	5401-5408	carried	_
31-5	5409-5412	out	_
31-6	5413-5418	using	_
31-7	5419-5423	each	_
31-8	5424-5432	thalamic	_
31-9	5433-5443	sub-region	_
31-10	5444-5446	as	_
31-11	5447-5448	a	_
31-12	5449-5453	seed	_
31-13	5454-5455	,	_
31-14	5456-5459	and	_
31-15	5460-5465	whole	_
31-16	5466-5471	brain	_
31-17	5472-5484	connectivity	_
31-18	5485-5489	maps	_
31-19	5490-5491	(	_
31-20	5492-5493	z	_
31-21	5494-5500	values	_
31-22	5501-5502	)	_
31-23	5503-5505	to	_
31-24	5506-5510	each	_
31-25	5511-5515	seed	_
31-26	5516-5520	were	_
31-27	5521-5531	calculated	_
31-28	5532-5533	.	_

32-1	5534-5546	Second-level	_
32-2	5547-5554	t-tests	_
32-3	5555-5559	were	_
32-4	5560-5569	performed	_
32-5	5570-5572	to	_
32-6	5573-5580	examine	_
32-7	5581-5593	differential	_
32-8	5594-5606	connectivity	_
32-9	5607-5614	between	_
32-10	5615-5628	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
32-11	5629-5637	patients	_
32-12	5638-5641	and	_
32-13	5642-5650	controls	_
32-14	5651-5653	in	_
32-15	5654-5657	the	_
32-16	5658-5663	whole	_
32-17	5664-5669	brain	_
32-18	5670-5671	.	_

33-1	5672-5675	Age	_
33-2	5676-5677	,	_
33-3	5678-5681	sex	_
33-4	5682-5683	,	_
33-5	5684-5691	smoking	_
33-6	5692-5698	status	_
33-7	5699-5700	,	_
33-8	5701-5709	regional	_
33-9	5710-5714	gray	_
33-10	5715-5721	matter	_
33-11	5722-5728	volume	_
33-12	5729-5733	from	_
33-13	5734-5744	anatomical	_
33-14	5745-5750	scans	_
33-15	5751-5752	,	_
33-16	5753-5759	motion	_
33-17	5760-5763	and	_
33-18	5764-5776	differential	_
33-19	5777-5783	motion	_
33-20	5784-5794	parameters	_
33-21	5795-5799	were	_
33-22	5800-5803	all	_
33-23	5804-5813	accounted	_
33-24	5814-5817	for	_
33-25	5818-5820	as	_
33-26	5821-5831	covariates	_
33-27	5832-5834	in	_
33-28	5835-5838	the	_
33-29	5839-5847	analysis	_
33-30	5848-5849	.	_

34-1	5850-5861	Significant	_
34-2	5862-5870	clusters	_
34-3	5871-5873	of	_
34-4	5874-5883	decreased	_
34-5	5884-5886	or	_
34-6	5887-5896	increased	_
34-7	5897-5905	thalamic	_
34-8	5906-5918	connectivity	_
34-9	5919-5923	were	_
34-10	5924-5934	identified	_
34-11	5935-5940	using	_
34-12	5941-5955	threshold-free	_
34-13	5956-5963	cluster	_
34-14	5964-5975	enhancement	_
34-15	5976-5977	.	_

35-1	5978-5981	The	_
35-2	5982-5991	IBASPM116	_
35-3	5992-5997	atlas	_
35-4	5998-5999	(	_
35-5	6000-6009	PickAtlas	_
35-6	6010-6018	software	_
35-7	6019-6020	,	_
35-8	6021-6025	Wake	_
35-9	6026-6032	Forest	_
35-10	6033-6043	University	_
35-11	6044-6045	,	_
35-12	6046-6051	North	_
35-13	6052-6060	Carolina	_
35-14	6061-6062	,	_
35-15	6063-6066	USA	_
35-16	6067-6068	)	_
35-17	6069-6072	was	_
35-18	6073-6077	used	_
35-19	6078-6080	to	_
35-20	6081-6089	identify	_
35-21	6090-6100	anatomical	_
35-22	6101-6108	regions	_
35-23	6109-6115	within	_
35-24	6116-6119	the	_
35-25	6120-6131	significant	_
35-26	6132-6140	clusters	_
35-27	6141-6142	(	_
35-28	6143-6147	note	_
35-29	6148-6152	that	_
35-30	6153-6155	an	_
35-31	6156-6166	anatomical	_
35-32	6167-6173	region	_
35-33	6174-6178	from	_
35-34	6179-6182	the	_
35-35	6183-6188	atlas	_
35-36	6189-6192	may	_
35-37	6193-6197	have	_
35-38	6198-6202	both	_
35-39	6203-6212	decreased	_
35-40	6213-6215	or	_
35-41	6216-6225	increased	_
35-42	6226-6238	connectivity	_
35-43	6239-6247	clusters	_
35-44	6248-6250	in	_
35-45	6251-6254	its	_
35-46	6255-6266	sub-regions	_
35-47	6267-6268	)	_
35-48	6269-6270	.	_

36-1	6271-6277	Effect	_
36-2	6278-6282	size	_
36-3	6283-6286	was	_
36-4	6287-6296	estimated	_
36-5	6297-6301	with	_
36-6	6302-6307	Cohen	_
36-7	6308-6309	’	_
36-8	6310-6311	s	_
36-9	6312-6314	d.	_
36-10	6315-6327	Correlations	_
36-11	6328-6335	between	_
36-12	6336-6344	thalamic	_
36-13	6345-6357	connectivity	_
36-14	6358-6361	and	_
36-15	6362-6369	disease	_
36-16	6370-6378	duration	_
36-17	6379-6380	,	_
36-18	6381-6394	antipsychotic	_
36-19	6395-6405	medication	_
36-20	6406-6412	dosage	_
36-21	6413-6414	,	_
36-22	6415-6419	BPRS	_
36-23	6420-6423	and	_
36-24	6424-6428	MoCA	_
36-25	6429-6435	scores	_
36-26	6436-6437	(	_
36-27	6438-6447	including	_
36-28	6448-6451	the	_
36-29	6452-6457	total	_
36-30	6458-6463	score	_
36-31	6464-6467	and	_
36-32	6468-6477	subscales	_
36-33	6478-6481	for	_
36-34	6482-6486	both	_
36-35	6487-6491	BPRS	_
36-36	6492-6495	and	_
36-37	6496-6500	MoCA	_
36-38	6501-6502	)	_
36-39	6503-6507	were	_
36-40	6508-6517	evaluated	_
36-41	6518-6523	using	_
36-42	6524-6532	adjusted	_
36-43	6533-6535	R2	_
36-44	6536-6540	from	_
36-45	6541-6547	linear	_
36-46	6548-6558	regression	_
36-47	6559-6560	.	_

37-1	6561-6565	Note	_
37-2	6566-6570	that	_
37-3	6571-6574	for	_
37-4	6575-6587	correlations	_
37-5	6588-6595	between	_
37-6	6596-6604	thalamic	_
37-7	6605-6617	connectivity	_
37-8	6618-6621	and	_
37-9	6622-6629	disease	_
37-10	6630-6638	duration	_
37-11	6639-6640	,	_
37-12	6641-6645	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
37-13	6646-6649	and	_
37-14	6650-6654	MoCA	http://maven.renci.org/NeuroBridge/neurobridge#TheMontrealCognitiveAssessment
37-15	6655-6661	scores	_
37-16	6662-6663	,	_
37-17	6664-6671	partial	_
37-18	6672-6684	correlations	_
37-19	6685-6689	were	_
37-20	6690-6700	calculated	_
37-21	6701-6705	with	_
37-22	6706-6709	age	_
37-23	6710-6711	,	_
37-24	6712-6719	smoking	_
37-25	6720-6726	status	_
37-26	6727-6730	and	_
37-27	6731-6741	medication	_
37-28	6742-6748	dosage	_
37-29	6749-6751	as	_
37-30	6752-6762	covariates	_
37-31	6763-6764	.	_

38-1	6765-6773	Multiple	_
38-2	6774-6785	comparisons	_
38-3	6786-6788	in	_
38-4	6789-6792	the	_
38-5	6793-6804	correlation	_
38-6	6805-6813	analysis	_
38-7	6814-6815	(	_
38-8	6816-6826	functional	_
38-9	6827-6839	connectivity	_
38-10	6840-6847	between	_
38-11	6848-6851	the	_
38-12	6852-6860	thalamus	_
38-13	6861-6864	and	_
38-14	6865-6873	multiple	_
38-15	6874-6882	cortical	_
38-16	6883-6890	regions	_
38-17	6891-6892	)	_
38-18	6893-6897	were	_
38-19	6898-6907	corrected	_
38-20	6908-6911	for	_
38-21	6912-6916	with	_
38-22	6917-6920	the	_
38-23	6921-6936	false-discovery	_
38-24	6937-6941	rate	_
38-25	6942-6943	(	_
38-26	6944-6952	adjusted	_
38-27	6953-6954	P	_
38-28	6955-6956	<	_
38-29	6957-6961	0.05	_
38-30	6962-6963	)	_
38-31	6964-6965	.	_

